Navignostics is a biotechnology company founded in 2022 as a spin-off from the University of Zurich Bodenmiller Lab. Their mission is to fight cancer by enabling personalized treatments through advanced spatial single-cell proteomics technology. They analyze tumor samples to determine the best way to target each cancerous growth, helping clinicians find the right therapies for their patients and supporting researchers in developing new cancer drugs.

Navignostics combines highly multiplex protein imaging with advanced data analytics to provide detailed insights into tumor and immune cell compositions. Their technology detects up to 50 proteins from a single tumor tissue section and uses imaging mass cytometry to create high-resolution digital images representing molecular tumor composition. Proprietary computational workflows quantify tumor features, support individualized treatment decisions with thorough PDF reports, and help drug developers identify patient groups most likely to benefit.

Headquartered in Horgen, Zurich, Switzerland, Navignostics has a growing team including scientists, lab technicians, software developers, and business experts. The company prides itself on values like trust in quality, curiosity, and collaborative growth. It is privately held with around 11-50 employees. Navignostics collaborates with clinics and pharmaceutical partners to improve clinical trial success and patient outcomes.

Navignostics is growing and often seeks new colleagues who share their values. Open positions are listed on their LinkedIn page. Contact details include an address at Tödistrasse 46a, 8810 Horgen, Switzerland, phone number +41 44 224 09 70, and email [email protected].